Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | Long-term follow-up of the TOURMALINE-MM1 trial

Paul Richardson • 14 May 2022
COMy 2022
Multiple Myeloma Antibodies Dexamethasone Ixazomib Lenalidomide
TOURMALINE-MM1

In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the long-term follow-up of the TOURMALINE-MM1 trial (NCT01564537) evaluating the safety and efficacy of ixazomib, lenalidomide, and dexamethasone for the treatment of relapsed/refractory (R/R) myeloma. Dr Richardson comments on some results from this trial and further explains the importance of interpreting overall survival data appropriately. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

More from Paul Richardson

1:35
Novel therapeutic options and quadruplet regimens for newly diagnosed multiple myeloma
Paul Richardson • 29 Sep 2023
2:51
ANCHOR and LIGHTHOUSE trials: melflufen in multiple myeloma
Paul Richardson • 29 Sep 2023
7:24
Session highlights: managing the aging population in myeloma & promising treatment options
Paul Richardson • 29 Sep 2023
2:59
Exploring the potential role of melflufen in myeloma & updates from the LIGHTHOUSE trial
Paul Richardson • 12 May 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals